Matinas BioPharma faces delisting risk from NYSE American

BEDMINSTER, N.J., Sept. 04, 2026 /CourierPR/ -- Matinas BioPharma Holdings, Inc. has received a notice of non-compliance from the NYSE American, putting the company at risk of delisting. On August 31, 2026, Matinas BioPharma received a formal notice stating that it does not meet the stockholders’ equity requirement for continued listing on the NYSE American. The company’s stockholders’ equity as of June 30, 2026, was $1.8 million, falling short of the $2.0 million threshold required by the NYSE American Company Guide for companies reporting losses from continuing operations and/or net losses in two of their three most recent fiscal years. Additionally, the company has not met the standards for the past two fiscal years.

As previously disclosed, Matinas BioPharma is also non-compliant with other sections of the NYSE American Company Guide, including Sections 1003(a)(ii) and 1003(a)(iii). The company faces the risk of delisting if it fails to regain compliance by October 2, 2027, or if it does not make sufficient progress during the planned period. The NYSE American had accepted a compliance plan submitted by Matinas BioPharma on May 4, 2026, but the company must still adhere to the terms of the plan to avoid delisting proceedings.

The NYSE American’s notice does not immediately affect the listing of Matinas BioPharma’s common stock, which will continue to be traded on the exchange during the compliance period. The company remains listed as a non-compliant issuer, and the .BC indicator, indicating non-compliance, will continue to be disseminated with its ticker symbol. This indicator will be removed once the company regains full compliance with the listing standards.

Matinas BioPharma, a biopharmaceutical company focused on lipid nanocrystal (LNC) platform delivery technology, is developing MAT2203, a potential oral treatment for invasive fungal infections. MAT2203 is designed to overcome the limitations of intravenous amphotericin B, which is currently associated with significant safety issues. The drug was successfully evaluated in the Phase 2 EnACT study and is planned to be further tested in a single Phase 3 registration trial as an oral step-down monotherapy in patients with limited treatment options for invasive aspergillosis.

CEO Jerome D. Jabbour stated, “We are committed to regaining compliance and are actively working on our plan to meet the NYSE American’s continued listing standards. Our ongoing business operations and reporting requirements remain unaffected. We will continue to monitor and report on our progress to the public.”

The company’s next steps will be crucial in determining its future on the NYSE American. Failure to comply could result in delisting, which would have significant implications for the company’s public presence and financial standing.